Chemical Nameobiltoxaximab
Dosage FormInjection (intravenous; 600 mg/6 mL)
Drug ClassMonoclonal antibodies
SystemSkin, Respiratory, Digestive
CompanyElusys Therapeutics Inc
Approval Year2016


  • To treat inhalational anthrax in combination with appropriate antibacterial drugs.
  • For prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Anthim (obiltoxaximab) Prescribing Information 2019Elusys Therapeutics, Inc., Parsippany, NJ